Recruiting

DWI vs. FDG PET

Sponsor:

UCLA

Code:

NCT06630845

Conditions

Metastatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fluorodeoxyglucose F18

Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)

Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)

General Electric (GE) SIGNA PET/MR

Study Details

Brief summary:

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Conditions

Metastatic Cancer

Study ID

NCT06630845

Start date

Feb 6, 2025

Status verified date

Mar, 2026

Completion date

Oct 31, 2029

Anticipated

Primary completion date

Oct 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age ≥ 18 years.
2. Non FDG PET imaging study scheduled to be performed within 60 days (before or after) of the research PET/MRI.
3. Ability to understand a written informed consent document, and the willingness to sign it.
4. Diagnosis of metastatic cancer.

Exclusion Criteria:

1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
2. Individuals with contraindications to MRI. This will be determined through review of the UCSF MRI screening form by qualified site personnel

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Whole Body DWI plus FDG PET/MRI

Participants will receive 5 to 10 Megabecquerel (MBq) +/- 10% of 18F-fluorodeoxyglucose as an intravenous injection and undergo a FDG PET/MRI scan that will extend from the vertex to the mid-thighs. Imaging will be performed from vertex to mid-thighs using standard protocol. Participants may also obtain an optional second FDG PET/MRI with DWI within 6 months.

Interventions

Fluorodeoxyglucose F18

Given IV as part of routine imaging

Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)

Imaging procedure

Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)

Imaging procedure done concurrently with PET/MRI

General Electric (GE) SIGNA PET/MR

Imaging device

Primary outcome measure

  • Proportion of lesions characterized as positive [ Time Frame: Up to 6 months ]

Central Contacts and Locations

Central contacts

Brad Kline

877-827-3222brad.kline@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Brad Kline

Brad.Kline@ucsf.edu

877-827-3222cancertrials@ucsf.edu

Principal Investigator:

Thomas Hope, MD

More Information

Sponsor

University of California, San Francisco

Last update posted

Apr 3, 2026

Last verified

Mar, 2026

Keywords

  • Imaging Study

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-04-03.